Table 2. Most Common Adverse Events (AEs) Independent of Causality, Reported in 20% or More of Patients in Either Treatment.
| Variable | No. (%) | |||
|---|---|---|---|---|
| Savolitinib, 600 mg (n = 33) | Sunitinib, 50 mg (n = 27) | |||
| All | Grade ≥3 | All | Grade ≥3 | |
| Any AE | 30 (91) | 14 (42) | 27 (100) | 22 (81) |
| Alanine aminotransferase increased | 8 (24) | 5 (15) | 3 (11) | 2 (7) |
| Anemia | 2 (6) | 0 | 12 (44) | 4 (15) |
| Aspartate aminotransferase increased | 8 (24) | 4 (12) | 5 (19) | 2 (7) |
| Blood creatinine increased | 9 (27) | 0 | 2 (7) | 0 |
| Cough | 4 (12) | 0 | 6 (22) | 0 |
| Decreased appetite | 1 (3) | 0 | 8 (30) | 1 (4) |
| Diarrhea | 0 | 0 | 6 (22) | 1 (4) |
| Dyspnea | 7 (21) | 1 (3) | 4 (15) | 0 |
| Hypertension | 1 (3) | 0 | 6 (22) | 4 (15) |
| Nausea | 2 (6) | 0 | 9 (33) | 0 |
| Edema peripheral | 11 (33) | 0 | 3 (11) | 0 |
| Palmar-plantar erythrodysesthesia syndrome | 0 | 0 | 7 (26) | 0 |
| Thrombocytopenia | 0 | 0 | 7 (26) | 2 (7) |
| Yellow skin | 0 | 0 | 4 (15) | 0 |